Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of ER Niacin/Laropiprant/Simvastatin Combination Tablet
NCT01294683Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2011
- Primary completion
- Jan 2012
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of niacin, laropiprant, simvastatin in hypercholesterolemia, mixed dyslipidemia, sponsored by Merck & Co.. Started Feb 2011; status: terminated.
02
Drugs
niacinlaropiprantsimvastatin
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT01294683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01294683.